SCHEDULE 13D: Major Investor Group Boosts Stake in NKGen Biotech to 47.2% Through New $2.5 Million Private Placement

CFIC-2015 NV Family Investments, LLC and its principals, Andrew and Peggy Cherng, have significantly increased their beneficial ownership in NKGen Biotech, Inc. to 47.2% through a recent $2.5 million private placement and associated warrants, signaling a strong investment interest and intent to monitor corporate governance.

Summary

• CFIC-2015 NV Family Investments, LLC, along with Andrew and Peggy Cherng, have jointly filed a Schedule 13D, reporting a beneficial ownership of 63,175,321 shares of NKGen Biotech, Inc. Common Stock.
• This represents 47.2% of the company's outstanding Common Stock, based on 74,750,212 shares outstanding as of May 9, 2025, plus the 59,008,655 shares beneficially owned by the reporting person pursuant to the 2025 Purchase Agreement and the 2025 Warrant.
• The increase in ownership stems from a private placement detailed in a Stock Purchase Agreement dated May 14, 2025, where CFIC-2015 purchased 19,669,552 shares for $2,500,000.00 in cash.
• In connection with this purchase, CFIC-2015 also received a warrant to acquire an additional 39,339,103 shares of Common Stock at an exercise price of $0.1271 per share.
• The total beneficial ownership includes shares and rights to acquire shares from both the 2025 transactions and previous agreements from August 2024, which included 2,083,333 shares and a right to acquire another 2,083,333 shares.
• The Reporting Persons state their acquisition is for investment purposes and they intend to monitor the company's performance and corporate governance, asserting stockholder rights as deemed necessary.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment and vote of confidence from a major investor group, providing capital to the company. However, the large stake and low warrant exercise price could imply potential future dilution and concentrated control, which introduces some caution.

Positives

• Significant capital injection of $2,500,000.00 into NKGen Biotech, Inc. through a private placement, providing crucial funding.
• Strong vote of confidence from a major investor group (CFIC-2015 NV Family Investments, LLC and the Cherngs), increasing their stake to 47.2% of the company.
• The investor group intends to actively monitor corporate governance and assert stockholder rights, potentially leading to improved oversight and strategic direction for the company.

Negatives

• The substantial increase in beneficial ownership by a single investor group to 47.2% could lead to significant control and influence over the company's direction, potentially limiting the influence of other shareholders.
• The issuance of a warrant for 39,339,103 shares at a low exercise price of $0.1271 per share, combined with the 19,669,552 shares purchased, indicates a low valuation per share for this capital raise, which could be dilutive to existing shareholders if the warrants are exercised.

Risks

• Potential for significant dilution to existing shareholders if the warrants to purchase 39,339,103 additional shares are exercised.
• Concentration of ownership: The Reporting Persons' 47.2% stake gives them substantial influence, which could impact corporate decisions and potentially limit the voice of minority shareholders.

Future Outlook

The Reporting Persons acquired the securities for investment purposes and intend to actively monitor NKGen Biotech, Inc.'s performance and corporate governance. They reserve the right to engage in discussions with management, the board, and other stockholders regarding business practices and governance policies, and will assert stockholder rights as deemed necessary.

Industry Context

This filing indicates a significant capital infusion into NKGen Biotech, a company operating in the biotech sector. Such private placements are common for biotech firms seeking funding for research, development, or operational expenses, especially those that may not yet be profitable or have consistent revenue streams. The substantial stake acquired by a single investor group suggests a belief in the company's long-term potential, which could be a positive signal within the often capital-intensive and high-risk biotech industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from warrant exercise; increased oversight and potential influence from a major investor; capital injection could stabilize or grow the company, benefiting long-term shareholders.
• Company (NKGen Biotech, Inc.): Receives $2.5 million in cash, providing capital for operations or development. Gains a significant, engaged investor.

Next Steps

• The Reporting Persons will monitor NKGen Biotech, Inc.'s performance and corporate governance.
• The Reporting Persons may engage in discussions with the Issuer's management, board of directors, and stockholders regarding business practices and governance policies.
• The Reporting Persons may assert stockholder rights as deemed necessary.
• CFIC-2015 has the right to acquire an additional 2,083,333 shares of Common Stock upon the purchase of up to $2,750,000 of convertible promissory notes from the Issuer, which would also include additional warrants.

Key Dates

Recommendation

Keywords

NKGen Biotech, CFIC-2015 NV Family Investments, Andrew Cherng, Peggy Cherng, Schedule 13D, Beneficial Ownership, Private Placement, Stock Purchase Agreement, Warrant, Common Stock, Investment, Corporate Governance, SEC Filing, Biotech Investment